HIV InfectionsPhase 1NCT00002008
An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
A Phase 1 study testing Sargramostim in people with HIV Infections and Cytopenias, run by Sandoz at 2 sites in United States.
Trial summary
To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC ) injection to patients with leukopenia in association… Read more about this study
- Who is it for?
- Ages 18 to 50 years, men only
- Conditions the study is for
- HIV Infections, Cytopenias
- What is being tested?
- Sargramostim
- How many people
- Not given
- Where
- 2 sitesUnited States
- Study dates
- Start not givento not given
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Patients must have:
- Serum antibody to HIV with or without evidence of HIV.
- Antigenemia.
- Anticipated survival of at least 6 months.
- Allowed:
- Kaposi's sarcoma.
Who cannot join
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- Malignancy other than Kaposi's sarcoma.
- Excessive diarrhea (more than 5 liquid or non-liquid stools per day).
- Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection.
- Primary hematologic or infectious disorders unrelated to AIDS virus infection.
Show all 22Show fewer
- Dementia or altered mental status that would prohibit the giving and understanding of informed consent.
- Patients with the following are excluded:
- History of malignancy other than Kaposi's sarcoma.
- Currently hospitalized or hospitalized within 4 weeks for the treatment of opportunistic infection.
- Prior Medication:
- Excluded within 3 weeks of study entry:
- Marrow suppressive medication.
- Excluded within 4 weeks of study entry:
- Any investigational drug.
- Prior Treatment:
- Excluded within 4 weeks of study entry:
- Systemic cytotoxic chemotherapy.
- Irradiation.
- Risk Behavior:
- Excluded within 3 months of study entry:
- Regular, excessive users of alcohol, hallucinogens, or agents which are addicting.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Beth Israel Deaconess - West Campus
Boston, Massachusetts, 02215
UCLA CARE Ctr
Los Angeles, California, 90095
About this study
To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC ) injection to patients with leukopenia in association with HIV infection.
- Conditions
- HIV Infections, Cytopenias
- Being tested
- Sargramostim
- Keywords
- Leukopenia, Drug Evaluation, Granulocyte-Macrophage Colony-Stimulating Factor
- Medical subject headings
- HIV Infections, Cytopenia, Leukopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SargramostimDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2001 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Masking
- None (open label)
Sponsor and investigators
- Lead sponsor
- Sandoz
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00002008
- Sponsor's protocol ID
- 067D
- Other IDs
- 106
- Status last verified
- Jan 1989
- First submitted
- 2 Nov 1999
- Last updated
- 24 Jun 2005
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2005. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia
- ClinicalTrials.gov ID
- NCT00002008
- Acronym / sponsor ID
- 067D
- Conditions
- HIV Infections, Cytopenias
- Keywords
- Leukopenia, Drug Evaluation, Granulocyte-Macrophage Colony-Stimulating Factor
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- SandozIndustry (pharma, biotech, devices)
- First posted
- 31 Aug 2001 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the safety, immunogenicity, biological activity, ad pharmacokinetics of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) human granulocyte-macrophage colony-stimulating factor ( GM-CSF ), given by subcutaneous ( SC ) injection to patients with leukopenia in association with HIV infection.
Study design
- Primary purpose
- Treatment
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Serum antibody to HIV with or without evidence of HIV.
- Antigenemia.
- Anticipated survival of at least 6 months.
- Allowed:
- Kaposi's sarcoma.
Key exclusion criteria (22 listed)
- Malignancy other than Kaposi's sarcoma.
- Excessive diarrhea (more than 5 liquid or non-liquid stools per day).
- Currently hospitalized or hospitalized within the last 4 weeks for the treatment of opportunistic infection.
- Primary hematologic or infectious disorders unrelated to AIDS virus infection.
- Dementia or altered mental status that would prohibit the giving and understanding of informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sargramostim | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2005.
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Sargramostim in people with HIV Infections and Cytopenias, run by Sandoz at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2005. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2005.